Cellectar Reports Recent Corporate Highlights and 2018 First Quarter Financial Results

Cellectar Granted Orphan Drug Designation for CLR 131 to Treat Rhabdomyosarcoma

2018 Annual Meeting of Stockholders

May 31, 2018 • 10:00am CDT